189 related articles for article (PubMed ID: 18705297)
21. Aminosalicylates.
Gross V
Dig Dis; 2012; 30(1):92-9. PubMed ID: 22572694
[TBL] [Abstract][Full Text] [Related]
22. Rectal administration of Lactobacillus casei DG modifies flora composition and Toll-like receptor expression in colonic mucosa of patients with mild ulcerative colitis.
D'Incà R; Barollo M; Scarpa M; Grillo AR; Brun P; Vettorato MG; Castagliuolo I; Sturniolo GC
Dig Dis Sci; 2011 Apr; 56(4):1178-87. PubMed ID: 20737210
[TBL] [Abstract][Full Text] [Related]
23. Treatment of diarrhea-predominant irritable bowel syndrome with mesalazine and/or Saccharomyces boulardii.
Bafutto M; Almeida JR; Leite NV; Costa MB; Oliveira EC; Resende-Filho J
Arq Gastroenterol; 2013; 50(4):304-9. PubMed ID: 24474234
[TBL] [Abstract][Full Text] [Related]
24. Acute diverticulitis of the colon--current medical therapeutic management.
Tursi A
Expert Opin Pharmacother; 2004 Jan; 5(1):55-9. PubMed ID: 14680435
[TBL] [Abstract][Full Text] [Related]
25. Oral delayed-release mesalazine: a review of its use in ulcerative colitis and Crohn's disease.
Prakash A; Markham A
Drugs; 1999 Mar; 57(3):383-408. PubMed ID: 10193690
[TBL] [Abstract][Full Text] [Related]
26. Effectiveness of different therapeutic strategies in preventing diverticulitis recurrence.
Tursi A; Elisei W; Giorgetti GM; Inchingolo CD; Nenna R; Picchio M; Maiorano M; Penna A; Lecca PG; Brandimarte G
Eur Rev Med Pharmacol Sci; 2013 Feb; 17(3):342-8. PubMed ID: 23426537
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of 5-ASA in the treatment of colonic diverticular disease.
Gatta L; Vakil N; Vaira D; Pilotto A; Curlo M; Comparato G; Leandro G; Ferro U; Lera M; Milletti S; Di Mario F
J Clin Gastroenterol; 2010 Feb; 44(2):113-9. PubMed ID: 19561530
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis.
Zocco MA; dal Verme LZ; Cremonini F; Piscaglia AC; Nista EC; Candelli M; Novi M; Rigante D; Cazzato IA; Ojetti V; Armuzzi A; Gasbarrini G; Gasbarrini A
Aliment Pharmacol Ther; 2006 Jun; 23(11):1567-74. PubMed ID: 16696804
[TBL] [Abstract][Full Text] [Related]
29. Effect of mesalazine on epithelial cell proliferation in colonic diverticular disease.
Tursi A; Brandimarte G; Elisei W; Giorgetti GM; Inchingolo CD; Aiello F
Dig Liver Dis; 2008 Sep; 40(9):737-42. PubMed ID: 18387861
[TBL] [Abstract][Full Text] [Related]
30. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses.
Kruis W; Schreiber S; Theuer D; Brandes JW; Schütz E; Howaldt S; Krakamp B; Hämling J; Mönnikes H; Koop I; Stolte M; Pallant D; Ewald U
Gut; 2001 Dec; 49(6):783-9. PubMed ID: 11709512
[TBL] [Abstract][Full Text] [Related]
31. Intermittent treatment with mesalazine in the prevention of diverticulitis recurrence: a randomised multicentre pilot double-blind placebo-controlled study of 24-month duration.
Parente F; Bargiggia S; Prada A; Bortoli A; Giacosa A; Germanà B; Ferrari A; Casella G; De Pretis G; Miori G;
Int J Colorectal Dis; 2013 Oct; 28(10):1423-31. PubMed ID: 23754545
[TBL] [Abstract][Full Text] [Related]
32. Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease.
Clemett D; Markham A
Drugs; 2000 Apr; 59(4):929-56. PubMed ID: 10804042
[TBL] [Abstract][Full Text] [Related]
33. Ulcerative Colitis Remission Status After Induction With Mesalazine Predicts Maintenance Outcomes: the MOMENTUM Trial.
Rubin DT; Bradette M; Gabalec L; Dobru D; Márquez J; Inglis S; Magee E; Solomon D; D'Haens G;
J Crohns Colitis; 2016 Aug; 10(8):925-33. PubMed ID: 26908939
[TBL] [Abstract][Full Text] [Related]
34. Maintenance treatment of ulcerative proctitis with mesalazine suppositories: a double-blind placebo-controlled trial. The Italian IBD Study Group.
d'Albasio G; Paoluzi P; Campieri M; Bianchi Porro G; Pera A; Prantera C; Sturniolo GC; Miglioli M
Am J Gastroenterol; 1998 May; 93(5):799-803. PubMed ID: 9625131
[TBL] [Abstract][Full Text] [Related]
35. Two mesalazine regimens in the prevention of the post-operative recurrence of Crohn's disease: a pragmatic, double-blind, randomized controlled trial.
Caprilli R; Cottone M; Tonelli F; Sturniolo G; Castiglione F; Annese V; Papi C; Viscido A; Cammà C; Corrao G; Latella G
Aliment Pharmacol Ther; 2003 Feb; 17(4):517-23. PubMed ID: 12622760
[TBL] [Abstract][Full Text] [Related]
36. Quality of life in uncomplicated symptomatic diverticular disease: is it another good reason for treatment?
Comparato G; Fanigliulo L; Aragona G; Cavestro GM; Cavallaro LG; Leandro G; Pilotto A; Nervi G; Soliani P; Sianesi M; Franzé A; Di Mario F
Dig Dis; 2007; 25(3):252-9. PubMed ID: 17827951
[TBL] [Abstract][Full Text] [Related]
37. Pathophysiology and Therapeutic Strategies for Symptomatic Uncomplicated Diverticular Disease of the Colon.
Scaioli E; Colecchia A; Marasco G; Schiumerini R; Festi D
Dig Dis Sci; 2016 Mar; 61(3):673-83. PubMed ID: 26458921
[TBL] [Abstract][Full Text] [Related]
38. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis.
Kamm MA; Lichtenstein GR; Sandborn WJ; Schreiber S; Lees K; Barrett K; Joseph R
Gut; 2008 Jul; 57(7):893-902. PubMed ID: 18272546
[TBL] [Abstract][Full Text] [Related]
39. A randomized trial comparing 4.8 vs. 2.4 g/day of oral mesalazine for maintenance of remission in ulcerative colitis.
Pica R; Cassieri C; Cocco A; Zippi M; Marcheggiano A; De Nitto D; Avallone EV; Crispino P; Occhigrossi G; Paoluzi P
Dig Liver Dis; 2015 Nov; 47(11):933-7. PubMed ID: 26391602
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of Lactobacillus paracasei sub. paracasei F19 on abdominal symptoms in patients with symptomatic uncomplicated diverticular disease: a pilot study.
Annibale B; Maconi G; Lahner E; De Giorgi F; Cuomo R
Minerva Gastroenterol Dietol; 2011 Mar; 57(1):13-22. PubMed ID: 21372765
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
